argenx has been through a volatile spell after a long run, and the recent swings now put a simple question in front of you as an investor: Is the current share price still in line with what the company's earnings can reasonably support?

• Over the past 5 years, argenx has delivered a share price gain of 185.3%, which puts a lot of weight on whether its earnings power has kept pace with that move.

• The company recently halted its Phase 3 Sjögren's trial for futility while reporting encouraging data for FB102 in celiac disease, a mix that can reshape expectations for future profit potential and the timing of any cash generation from its pipeline.

• The analysts covering argenx have run their own numbers. See what analysts think argenx's shares could be worth .

The issue now is whether argenx's current valuation can be explained by its earnings profile once you strip away the recent news swings and focus on the underlying business performance.

If you are weighing argenx after this trial setback and pipeline update, it can help to compare it with other companies by screening for 127 healthcare AI stocks

Does argenx Look Fairly Valued on Earnings?

The P/E ratio fits argenx because earnings are already positive and investors have a concrete profit base to compare with the share price. On this yardstick, argenx trades on about 29.7x earnings, which is above the broader biotech industry average of roughly 25.0x but below the peer group average of about 36.3x. The tailored fair multiple implied by its fundamentals sits close to the current figure, so the market is not assigning a clear premium or discount based on earnings alone.

Because the halted Sjögren's trial removes one potential earnings stream while the FB102 celiac data points to a different route to future profits, the current P/E suggests investors are weighing near term pipeline risk against an already established earnings base rather than pricing in an aggressive rerating. For anyone tracking argenx, the key question is whether that roughly mid range position between industry and peers still feels appropriate once the updated trial mix and earnings profile are factored in. Explore the numbers behind argenx's P/E valuation .

The argenx Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the argenx valuation puzzle leaves off. They spell out which combinations of future growth, margins and earnings would need to occur for the stock to appear meaningfully higher or lower than today's price, and each one ties a specific fair value to a clear story about argenx's potential catalysts and key risks. This allows you to track over time which version of events seems closest to reality on the Community page.